Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
暂无分享，去创建一个
Z. Estrov | G. Garcia-Manero | J. Cortes | K. Patel | F. Ravandi | Koichi Takahashi | E. Jabbour | N. Daver | S. Pierce | C. Bueso-Ramos | X. Wang | S. Faderl | S. Pierce | K. Patel | J. Cortes | Yue Wei | H. Yang | Y. Wei | K. Takahashi | H. Kantarjian | X. Wang | R. Luthra | Hong Yang